Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib
Takeda Exercises its Option with Denali to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin
Shots:
- Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical development, regulatory, and sales milestone for both programs along with royalties
- The acquisition will bolster Calithera’s precision oncology pipeline of clinical-stage targeted therapies i.e., sapanisertib (TORC 1/2 inhibitor) and mivavotinib (SYK inhibitor). Both compounds as monothx. demonstrated clinical activity with the higher potential in biomarker-defined cancer-patient populations
- Additionally, Calithera plans to start a P-II study of sapanisertib for sq.NSCLC and mivavotinib for DLBCL with biomarker specific populations in 2022
Click here to read the full press release/ article | Ref: Globe Newswire | Image: Pharmaceutical Technology